Drugs / Influenza virus split vaccine
Influenza virus split vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07302256 | Dec 2025 → Aug 2026 overdue | influenza | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07327398 | Jan → Sep 2026 overdue | influenza | Shanghai Institute Of Biological Products | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05212623 Comparator | Oct 2021 → Jan 2022 | influenza | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza virus split vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07327398 ↗ |
| Known as | IIV3 | “a trivalent inactivated influenza vaccine (IIV3) at 0.25 mL including A/H1N1, A/H3N2 and B/Victoria” NCT05212623 ↗ |
| Known as | trivalent inactivated influenza vaccine | “a trivalent inactivated influenza vaccine (IIV3) at 0.25 mL including A/H1N1, A/H3N2 and B/Victoria” NCT05212623 ↗ |
| Modality | Vaccine | “influenza vaccine” NCT05212623 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT05212623 ↗ |